Retatrutide

Retatrutide is a novel triple receptor agonist peptide that targets the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). Due to its unique mechanism of action, this new drug has the potential to treat obesity-related metabolic disorders and the diseases caused by them. The results of Phase II clinical trials show that significant weight loss was observed in overweight and obese adults, with an average weight reduction of 17.5% at 24 weeks and 24.4% at 48 weeks respectively.

In the clinical study on non-alcoholic fatty liver disease, a randomized, double-blind, placebo-controlled trial was set up. Participants (n = 98) were randomly assigned to receive subcutaneous injections of Retatrutide (at doses of 1mg, 4mg, 8mg, or 12mg) or placebo once a week for 48 weeks. At 24 weeks relative to the baseline, the mean changes in liver fat were -42.9% (1mg), -57.0% (4mg), -81.4% (8mg), -82.4% (12mg), and +0.3% (placebo). At 24 weeks, 27% (1mg), 52% (4mg), 79% (8mg), 86% (12mg), and 0% (placebo) of the participants had normal liver fat (that is, liver fat content < 5%). The reduction in liver fat was significantly associated with changes in body weight, abdominal fat, and metabolic indicators related to improvements in insulin sensitivity and lipid metabolism.